What to Look for in Monsanto Earnings

Photo of Chris Lange
By Chris Lange Updated Published
What to Look for in Monsanto Earnings

© Thinkstock

Monsanto Co. (NYSE: MON) is set to share its latest quarterly earnings before the markets open on Wednesday. The consensus estimates from Thomson Reuters call for $2.44 in earnings per share (EPS) and $4.76 billion in revenue. The same period from the previous year had $2.89 in EPS on $5.20 billion in revenue.

The company provides agricultural products for farmers worldwide. It operates in two segments: Seeds and Genomics, and Agricultural Productivity. Monsanto has met with controversy in recent years as many people protest the use and development of genetically modified organisms (GMOs).

While agriculture is weak at the moment, low prices lead to good income picks to help out with what may be a long wait. Long-term population trends are not declining, and prices eventually must rise. In the meantime, there are some really attractive value plays in the sector.

[nativounit]

Recently, the U.S. Securities and Exchange Commission (SEC) recently announced that Monsanto has agreed to pay an $80 million penalty and retain an independent compliance consultant to settle charges that it violated accounting rules and misstated company earnings as it pertained to its flagship product Roundup. At the same time, three accounting and sales executives also agreed to pay penalties to settle charges against them. Note that this company has a total market cap of $38 billion.

A few analysts weighed in on Monsanto prior to the earnings report:

  • Sanford Bernstein has a Sell rating with an $80 price target.
  • Citigroup downgraded to a Neutral rating from Buy and lowered its price target to $95 from $105.
  • Goldman Sachs downgraded to a Sell rating from Neutral and lowered its price target to $84 from $86.

So far in 2016 Monsanto has underperformed the broad markets with the stock down 11% year to date. Over the past 52-weeks the stock is down 24%.

Shares of Monsanto were last trading at $86.71. That was within a 52-week trading range of $81.22 to $123.82. The consensus price target is $99.84.

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Top Gaining Stocks

DELL Vol: 42,366,555
NTAP Vol: 15,911,807
NOW Vol: 68,243,561
IBM
IBM Vol: 28,527,546
HPE Vol: 86,996,387

Top Losing Stocks

CTRA Vol: 73,319,495
CLX Vol: 4,744,001
RMD Vol: 3,526,686
INTC Vol: 191,680,425
SWKS Vol: 5,407,806